{"attribution": {"fr": "M. Matthew Kellway", "en": "Mr. Matthew Kellway"}, "politician_url": "/politicians/matthew-kellway/", "url": "/debates/2013/6/14/matthew-kellway-1/", "h3": {"fr": "Question no 1340", "en": "Question No. 1340"}, "h1": {"fr": "Affaires Courantes", "en": "Routine Proceedings"}, "related": {"document_speeches_url": "/speeches/?document=%2Fdebates%2F2013%2F6%2F14%2F"}, "content": {"fr": "<p data-HoCid=\"3413104\"> En ce qui concerne les centres de pr\u00e9l\u00e8vement de plasma sanguin \u00e0 but lucratif propos\u00e9s \u00e0 Toronto et \u00e0 Hamilton (Ontario): <em>a</em>) quand les exploitants des centres de pr\u00e9l\u00e8vement de plasma sanguin \u00e0 but lucratif propos\u00e9s ont-ils contact\u00e9 Sant\u00e9 Canada; <em>b</em>) combien de consultations ont eu lieu entre Sant\u00e9 Canada et les exploitants des centres de pr\u00e9l\u00e8vement propos\u00e9s; <em>c</em>) combien de consultations ont eu lieu entre Sant\u00e9 Canada et (i) la Soci\u00e9t\u00e9 canadienne du sang, (ii) la province de l\u2019Ontario; <em>d</em>) quand ces consultations ont-elles eu lieu ou, si aucune consultation n\u2019a eu lieu, comment Sant\u00e9 Canada a-t-il d\u00e9termin\u00e9 que des consultations n\u2019\u00e9taient pas n\u00e9cessaires; <em>e</em>) quand l\u2019endroit des centres de pr\u00e9l\u00e8vement propos\u00e9s a-t-il \u00e9t\u00e9 approuv\u00e9; <em>f</em>) quel processus les exploitants des centres de pr\u00e9l\u00e8vement propos\u00e9s ont-ils suivi pour obtenir l\u2019approbation de l\u2019endroit choisi pour les centres de pr\u00e9l\u00e8vement; <em>g</em>) quelle est la politique de Sant\u00e9 Canada relative \u00e0 l\u2019exploitation de centres de pr\u00e9l\u00e8vement de plasma sanguin \u00e0 but lucratif au Canada; <em>h</em>) quelle est la politique de Sant\u00e9 Canada relative \u00e0 l\u2019application des recommandations de la Commission d\u2019enqu\u00eate sur l\u2019approvisionnement en sang du Canada (rapport Krever); <em>i</em>) quelles lois, r\u00e8glements, processus de v\u00e9rification, etc. sont actuellement en place pour assurer la s\u00e9curit\u00e9 de l\u2019approvisionnement en sang au Canada; <em>j</em>) en ce qui concerne l\u2019assurance de la s\u00e9curit\u00e9 de l\u2019approvisionnement en sang au Canada, quel est le r\u00f4le de r\u00e9glementation (i) de Sant\u00e9 Canada, (ii) de la province, (iii) de la Soci\u00e9t\u00e9 canadienne du sang; <em>k</em>) quel r\u00f4le la Soci\u00e9t\u00e9 canadienne du sang joue-t-elle dans l\u2019\u00e9tablissement ou la r\u00e9glementation des centres de pr\u00e9l\u00e8vement de plasma sanguin \u00e0 but lucratif au Canada; <em>l</em>) que comporte le processus de v\u00e9rification de Sant\u00e9 Canada li\u00e9 \u00e0 la d\u00e9livrance d\u2019une licence aux centres de pr\u00e9l\u00e8vement de plasma sanguin \u00e0 but lucratif au Canada; <em>m</em>) quelle information les exploitants fournissent-ils \u00e0 Sant\u00e9 Canada; <em>n</em>) \u00e0 quelle fr\u00e9quence Sant\u00e9 Canada proc\u00e8de-t-elle \u00e0 une v\u00e9rification de ces centres de pr\u00e9l\u00e8vement; <em>o</em>) quelles mesures Sant\u00e9 Canada et la Food and Drug administration des \u00c9tats-Unis prennent-ils pour assurer la s\u00e9curit\u00e9 des produits de plasma sanguin achet\u00e9s aux \u00c9tats-Unis?</p>", "en": "<p data-HoCid=\"3413104\">With regard to the issue of the proposed for-profit blood plasma clinics in Toronto and Hamilton, Ontario: (<em>a</em>) when was Health Canada approached by the operators of the proposed for-profit blood plasma clinics; (<em>b</em>) how many consultations took place between Health Canada and the operators of the proposed for-profit blood plasma clinics; (<em>c</em>) how many consultations took place between Health Canada and (i) Canadian Blood Services, (ii) the province of Ontario; (<em>d</em>) when did these consultations take place and if no consultations took place, how did Health Canada determine that consultations were not necessary; (<em>e</em>) when were the locations for the proposed clinics approved; (<em>f</em>) what process did the operators of the proposed for-profit blood plasma clinics follow to obtain approval for the location of the clinics; (<em>g</em>) what is Health Canada\u2019s policy on the operation of for-profit blood plasma clinics in Canada; (<em>h</em>) what is Health Canada\u2019s policy with regard to following the recommendations of the Royal Commission of Inquiry on the Blood System in Canada (\u201cKrever report\u201d); (<em>i</em>) what existing statutes, regulations, auditing processes, etc. are in place to ensure the safety of Canada\u2019s blood supply; (<em>j</em>) with regard to ensuring the safety of Canada\u2019s blood supply, what is the regulatory role of (i) Health Canada, (ii) the province, (iii) Canadian Blood Services; (<em>k</em>) what role does Canadian Blood Services play in the establishment or regulation of for-profit blood plasma clinics in Canada; (<em>l</em>) what does Health Canada\u2019s auditing process for licensing for-profit blood plasma clinics in Canada involve; (<em>m</em>) what information is provided to Health Canada by the operators; (<em>n</em>) how often does Health Canada audit these clinics; and (<em>o</em>) what is the relationship between Health Canada and the U.S. Food and Drug Administration in ensuring the safety of blood plasma products purchased from the United States of America? </p>"}, "h2": {"fr": "Questions transform\u00e9es en ordres de d\u00e9p\u00f4t de documents", "en": "Questions Passed as Orders for Returns"}, "document_url": "/debates/2013/6/14/", "time": "2013-06-14 12:15:00", "source_id": "p3413104", "politician_membership_url": "/politicians/memberships/4071/", "procedural": false}